Deferasirox

Generic Name: Deferasirox

Brand Names: Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₅N_₃O_₄

CAS Number: 201530-41-8

Unique Ingredient Identifier: V8G4MOF2V9

Background: Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions: Chronic Iron Overload

Associated Therapies: -

Clinical Trials

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Recruiting

Conditions: Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2020-06-09

Last Posted Date: 2023-10-10

Lead Sponsor: University of Pisa

Target Recruit Count: 39

Registration Number: NCT04423237

Locations: 🇮🇹
IRCCS Burlo Garofolo, Trieste, Italy

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Deferasirox

First Posted Date: 2019-04-19

Last Posted Date: 2022-11-21

Lead Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS

Target Recruit Count: 11

Registration Number: NCT03920657

Locations: 🇮🇹
Ospedale Niguarda, Milano, Italy
🇮🇹
Ospedale Businco, Cagliari, Italy
🇮🇹
AO Bianchi Melacrino Morelli, Reggio Calabria, Italy

and more 7 locations

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Phase 2

Completed

Conditions: Myelodysplasia

Interventions: Drug: Deferasirox

First Posted Date: 2018-01-02

Last Posted Date: 2024-12-16

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 39

Registration Number: NCT03387475

Locations: 🇫🇷
CHU de GRENOBLE ALPES, Grenoble, France

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

Phase 4

Completed

Conditions: Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2017-12-13

Last Posted Date: 2020-08-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT03372083

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Anemia

Interventions: Drug: Deferasirox
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-10-25

Last Posted Date: 2020-07-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT02943668

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major

Not Applicable

Conditions: AL-Hijama in Thalassmia Major

Interventions: Procedure: Al-hijamah
Drug: Deferasirox

First Posted Date: 2016-05-04

Last Posted Date: 2017-04-25

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT02761395

Locations: 🇪🇬
Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Phase 3

Completed

Conditions: Chronic Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2016-03-28

Last Posted Date: 2020-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT02720536

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Procedure: Bone marrow aspirate
Drug: Deferasirox

First Posted Date: 2016-01-26

Last Posted Date: 2018-08-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT02663752

Locations: 🇧🇪
Novartis Investigative Site, Liege, Belgium

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

Not Applicable

Conditions: Beta-Thalassemia
Iron Overload

Interventions: Drug: Amlodipine
Drug: Deferasirox

First Posted Date: 2015-06-17

Last Posted Date: 2016-10-26

Lead Sponsor: Kevin H.M. Kuo, MD, MSc, FRCPC

Target Recruit Count: 60

Registration Number: NCT02474420

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens

Phase 1

Conditions: Acute Myeloid Leukemia
Acute Lymphoid Leukemia

Interventions: Drug: Cytarabine
Drug: Deferasirox

First Posted Date: 2015-04-09

Last Posted Date: 2016-02-25

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT02413021

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy